Humana Inc. (HUM): Price and Financial Metrics

Humana Inc. (HUM)

Today's Latest Price: $382.33 USD

13.52 (-3.42%)

Updated Jan 27 3:22pm

Add HUM to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 8 in Medical - Health Insurance

See all "A" rated Strong Buy stocks

HUM Stock Summary

  • HUM has a market capitalization of $52,387,363,378 -- more than approximately 95.65% of US stocks.
  • Humana Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.83% of US equities in our set.
  • The volatility of Humana Inc's share price is greater than that of merely 1.46% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Humana Inc are PGR, DG, MMC, EMR, and RELX.
  • Visit HUM's SEC page to see the company's official filings. To visit the company's web site, go to

HUM Stock Price Chart Interactive Chart >

Price chart for HUM

HUM Price/Volume Stats

Current price $382.33 52-week high $474.70
Prev. close $395.85 52-week low $208.25
Day low $374.50 Volume 1,885,448
Day high $391.50 Avg. volume 1,101,708
50-day MA $408.23 Dividend yield 0.63%
200-day MA $402.03 Market Cap 50.60B

Humana Inc. (HUM) Company Bio

Humana operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. The company was founded in 1964 and is based in Louisville, Kentucky.

HUM Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$382.33$2310.34 484%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Humana Inc. To summarize, we found that Humana Inc ranked in the 82th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 486.5%. In terms of the factors that were most noteworthy in this DCF analysis for HUM, they are:

  • HUM's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 26.04% of tickers in our DCF set.
  • The weighted average cost of capital for the company is 8. This value is greater than merely 20.97% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Humana Inc? See GTS, VMD, ASNB, MODV, and HNGR.

HUM Latest News Stream

Event/Time News Detail
Loading, please wait...

HUM Latest Social Stream

Loading social stream, please wait...

View Full HUM Social Stream

Latest HUM News From Around the Web

Below are the latest news stories about Humana Inc that investors may wish to consider to help them evaluate HUM as an investment opportunity.

Monogram Health Announces Availability of Kidney Disease Care Coordination Services for Humana Members in Tennessee and Alabama

Monogram Health announced today that it is expanding its collaboration with leading health and wellness company Humana Inc. (NYSE: HUM). Through an agreement now in effect, Monogram is providing care coordination services in Alabama and Tennessee for eligible Humana Medicare Advantage and Commercial health plan members with chronic kidney disease (CKD) or End Stage Renal Disease (ESRD). This is in addition to providing such services as previously contracted with Humana in two other states, Louisiana and Mississippi.

Yahoo | January 26, 2021

Partners in Primary Care Announces 2021 Growth Plans for Its Senior-Focused Care Facilities

Partners in Primary Care announces 2021 growth plans for its senior-focused care facilities.

Yahoo | January 26, 2021

Humana Names Nwando Olayiwola, M.D., Chief Health Equity Officer

LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health and well-being company Humana Inc. (NYSE: HUM) has named Nwando Olayiwola, M.D., MPH, FAAFP, to the position of Senior Vice President and Chief Health Equity Officer. In this newly created role, Dr. Olayiwola will report directly to Humana Chief Medical and Corporate Affairs Officer William Shrank, M.D., and will set direction and establish strategy to promote health equity across all Humana lines of business, including its care delivery assets.

Business Wire | January 25, 2021

Barclays Stick to Their Buy Rating for Humana Inc By

Barclays Stick to Their Buy Rating for Humana Inc | January 17, 2021

Humana Healthy Horizons and The Humana Foundation Commit More Than $2.5 Million to COVID-19 Relief in Texas

AUSTIN, Texas--(BUSINESS WIRE)--Humana Healthy Horizons and The Humana Foundation commit more than $2.5 million to COVID-19 relief in Texas.

Business Wire | January 14, 2021

Read More 'HUM' Stories Here

HUM Price Returns

1-mo -6.65%
3-mo -3.49%
6-mo -2.28%
1-year 9.10%
3-year 35.05%
5-year 142.35%
YTD -6.81%
2020 12.71%
2019 28.94%
2018 15.89%
2017 22.60%
2016 14.85%

HUM Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full HUM Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8783 seconds.